Recent events
Recent events tied to this brand in public sources.
Back to profile13 entries
2026
MSD appoints Mary Srethapakdi as Managing Director for the Philippines
MSD in the Philippines, a trade name of Merck & Co., Inc, announced the appointment of Mary Srethapakdi as managing director for the Philippines, while she concurrently leads MSD's operations in Thailand. She succeeds Andreas Riedel, who has been appointed Managing Director for MSD Vietnam.
2021
NOXXON and MSD collaborate on NOX-A12 study
NOXXON and MSD entered a collaboration for MSD to provide pembrolizumab (Keytruda) and expert advice for the OPTIMUS study of NOX-A12 in second-line pancreatic cancer.
2021
WEHI and MSD establish researcher exchange collaboration
WEHI and MSD established a three-year exchange program under which WEHI researchers can be seconded to MSD’s Research Laboratories; the agreement also gives MSD an exclusive option to license WEHI intellectual property.
2021
FDA approves Keytruda and Lenvima combination for advanced kidney cancer
The FDA approved MSD's Keytruda and Eisai's Lenvima combination as first-line treatment for adults with advanced renal cell carcinoma.
2021
BioInvent and MSD enter a clinical-trial collaboration for BI-1808 and KEYTRUDA
BioInvent announced a second clinical-trial collaboration and supply agreement with MSD to evaluate BioInvent’s BI-1808 with MSD’s KEYTRUDA in a Phase 1/2a trial involving patients with lung and ovarian cancer.
2021
Alkermes and MSD enter clinical trial collaboration
Alkermes announced a clinical trial collaboration and supply agreement with MSD for a planned phase 3 study evaluating nemvaleukin alfa in combination with KEYTRUDA in patients with platinum-resistant ovarian cancer. Alkermes is responsible for conducting the study, which was planned to initiate in the second half of 2021.
2021
FDA approves Novocure application to initiate KEYNOTE-B36 trial
Novocure reported that the U.S. FDA approved its investigational device exemption application to initiate the KEYNOTE-B36 phase 2 pilot trial studying TTFields with pembrolizumab in first-line non-small cell lung cancer.
2020
Sanofi and MSD agree to test THOR-707 with Keytruda
Sanofi entered an agreement with MSD to collaborate on a phase II trial evaluating Sanofi's investigational candidate THOR-707 alongside MSD's Keytruda.
2020
QBiotics and MSD clinical collaboration
QBiotics announced that it had entered into an agreement with MSD to evaluate tigilanol tiglate in combination with Keytruda in patients with unresectable melanoma.
2020
MSD announces plan to acquire Takeda’s Dunboyne facility
MSD announced plans to acquire Takeda’s biologics manufacturing plant in Dunboyne, Ireland. The companies expected the staff consultation and transfer process to be completed in mid-September; the acquisition was not reported as completed.
2020
A-Bio and MSD announce clinical research collaboration
A-Bio and MSD announced a clinical research collaboration to study APG-115 combined with KEYTRUDA in patients with advanced solid tumors. A-Bio will support the open-label Ib/II clinical study.
2020
MSD exercises option to use Vaxxas vaccine platform
Vaxxas announced that MSD exercised an option to use Vaxxas’ High Density Microarray Patch platform for a vaccine candidate. MSD gained exclusive worldwide rights to develop and commercialize an undisclosed vaccine using the technology.
2020
InxMed and MSD enter clinical collaboration
InxMed announced a clinical collaboration with an MSD subsidiary to evaluate IN10018 in combination with pembrolizumab in patients with pancreatic cancer. InxMed will sponsor the study, and MSD will provide pembrolizumab for it.